2.82Open2.82Pre Close0 Volume0 Open Interest27.00Strike Price0.00Turnover0.00%IV-27.87%PremiumDec 20, 2024Expiry Date8.09Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Rigel Pharmaceuticals Stock Discussion
whoa! some Dip
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more freque...
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Let's break 30.+
27.+
Let's Get 30.+
No comment yet